Want to see BDTX full AI Analyst Report?
Top Page
Black Diamond Therapeutics
(NASDAQ:BDTX)
Select Model
Select Model
Rating:48Neutral
Price Target:
$2.00
▼(-10.71% Downside)
Action:Reiterated
Date:10/21/26
The score is held back primarily by weak and inconsistent financial performance (TTM zero revenue, sizable losses, and ongoing cash burn), partially offset by a relatively supportive balance sheet with low leverage. Technicals are modestly constructive in the near term but not strong enough to outweigh fundamentals, and valuation is constrained by a negative P/E and no dividend yield support.
Positive Factors
Conservative leverage
Debt of about $17.0M against $96.1M of equity implies conservative leverage, giving BDTX more flexibility to fund development and absorb operating volatility than a highly indebted biotech. This supports resilience, although it does not eliminate cash needs.
Negative Factors
No recurring current revenue
Zero trailing revenue alongside sizable operating and net losses leaves BDTX without current recurring commercial support for its research programs. Continued absence of revenue would require the company to rely on financing, partnerships, or future pipeline success to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative leverage
Debt of about $17.0M against $96.1M of equity implies conservative leverage, giving BDTX more flexibility to fund development and absorb operating volatility than a highly indebted biotech. This supports resilience, although it does not eliminate cash needs.
Read all positive factors
Black Diamond Therapeutics (BDTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$108.01M
Dividend YieldN/A
Average Volume (3M)760.95K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue Growth-100.00%
EPS Growth-392.92%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.74
Shares Outstanding57,453,747
10 Day Avg. Volume1,028,324
30 Day Avg. Volume760,953
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.23
Price to Sales (P/S)1.97
P/FCF Ratio4.67
Enterprise Value/Market Cap0.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-466.42
Enterprise Value/Ebitda-0.31
Forecast
1Y Price Target
$10.33Price Target Upside361.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$7.14M
Black Diamond Therapeutics Business Overview & Revenue Model
Company Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is ...
How the Company Makes Money
BDTX is a clinical-stage biotechnology company and, as such, it generally does not generate recurring commercial product revenue unless it has an approved product (null). Its funding and revenue sources typically come from (i) collaboration and li...
Black Diamond Therapeutics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
31
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 70.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.00K | 69.67M | 0.00 | -437.00K | 0.00 | 0.00 |
| EBITDA | -40.88M | 22.69M | -69.33M | -82.00M | -90.66M | -125.39M |
| Net Income | -42.55M | 22.37M | -69.68M | -82.44M | -91.17M | -125.60M |
Balance Sheet | ||||||
| Total Assets | 125.03M | 143.01M | 122.64M | 158.57M | 156.25M | 247.68M |
| Cash, Cash Equivalents and Short-Term Investments | 110.51M | 128.65M | 98.58M | 131.40M | 122.81M | 209.79M |
| Total Debt | 16.97M | 18.78M | 22.19M | 25.30M | 28.14M | 28.46M |
| Total Liabilities | 28.94M | 30.80M | 39.35M | 41.83M | 40.56M | 51.78M |
| Stockholders Equity | 96.09M | 112.21M | 83.28M | 116.74M | 115.69M | 195.90M |
Cash Flow | ||||||
| Free Cash Flow | -32.01M | 29.61M | -62.30M | -66.75M | -85.27M | -102.86M |
| Operating Cash Flow | -32.01M | 29.61M | -62.30M | -66.72M | -85.08M | -100.15M |
| Investing Cash Flow | 22.08M | -44.91M | 16.97M | 16.35M | 53.37M | 130.61M |
| Financing Cash Flow | -30.00K | -146.00K | 25.55M | 71.93M | 177.00K | 729.00K |
Black Diamond Therapeutics Technical Analysis
Negative
2.24
Price Trends
1.98
Negative
1.91
Negative
2.22
Negative
Market Momentum
<0.01
Negative
48.89
Neutral
76.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDTX, the sentiment is Negative. The current price of 2.24 is above the 20-day moving average (MA) of 1.85, above the 50-day MA of 1.98, and above the 200-day MA of 2.22, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 48.89 is Neutral, neither overbought nor oversold. The STOCH value of 76.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDTX.
Black Diamond Therapeutics Risk Analysis
Black Diamond Therapeutics disclosed 81 risk factors in its most recent earnings report. Black Diamond Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Black Diamond Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $108.01M | -2.54 | -38.80% | ― | -100.00% | -392.92% | |
47 Neutral | $183.84M | -2.17 | 44.63% | ― | 3.03% | 57.71% | |
45 Neutral | $64.05M | -2.04 | 1020.21% | ― | ― | 2.05% | |
42 Neutral | $89.24M | -1.07 | -116.86% | ― | -98.25% | 76.83% | |
42 Neutral | $11.74M | -0.02 | 77.63% | ― | 6.81% | 11.95% | |
40 Underperform | $13.77M | -0.22 | -108.72% | ― | 2.15% | 17.34% |
* Healthcare Sector Average
BDTX
Black Diamond Therapeutics
1.88
-2.07
-52.41%
KZIA
Kazia Therapeutics
7.81
0.51
6.99%
ONCY
Oncolytics Biotech
0.50
-0.71
-58.51%
KPTI
Karyopharm Therapeutics
0.52
-5.90
-91.95%
ADCT
ADC Therapeutics
1.44
-2.85
-66.43%
TCRX
TScan Therapeutics
0.20
-2.08
-91.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.